City File: Drugs worry
MEDEVA, the troubled drugs group, will remind shareholders on Tuesday that it is looking for a new chief executive. Bernard Taylor - the former chief executive of Glaxo and no relation to the Martin Taylor who has just joined Barclays - needs to strengthen his board to restore investor confidence.
The half-year profits figure will be meaningless, as it will depend on whether the group has already written off its pounds 10m of extra stocks in its US IMS drug-delivery business. Assuming it has not, pre-tax profits will be about 20 per cent up on last year's pounds 17m. Analysts are predicting a full-year total of pounds 42m. But the market is fearing further bad news and the shares are a gamble at best.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies